FierceBiotech 2026-01-30 Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’
FierceBiotech 2026-01-30 Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
FierceBiotech 2026-01-30 Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
FierceBiotech 2026-01-29 Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
FierceBiotech 2026-01-29 Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
FierceBiotech 2026-01-29 Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
FierceBiotech 2026-01-29 Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor
FierceBiotech 2026-01-29 AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
FierceBiotech 2026-01-29 Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
FierceBiotech 2026-01-28 Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says
FierceBiotech 2026-01-28 New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill
FierceBiotech 2026-01-28 Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M